Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sympathetic Nervous System | 19 | 2020 | 64 | 5.160 |
Why?
|
| Medulla Oblongata | 4 | 2018 | 40 | 1.930 |
Why?
|
| Spleen | 10 | 2016 | 199 | 1.820 |
Why?
|
| Aging | 7 | 2017 | 764 | 1.540 |
Why?
|
| Receptors, Neurotransmitter | 2 | 2018 | 24 | 1.110 |
Why?
|
| Rats | 19 | 2020 | 3701 | 0.830 |
Why?
|
| Renal Circulation | 3 | 2020 | 20 | 0.770 |
Why?
|
| Heart Rate | 11 | 2017 | 261 | 0.750 |
Why?
|
| Brain Stem | 3 | 2018 | 51 | 0.750 |
Why?
|
| Fever | 2 | 2013 | 63 | 0.700 |
Why?
|
| Blood Pressure | 12 | 2018 | 662 | 0.700 |
Why?
|
| Rats, Sprague-Dawley | 13 | 2017 | 1737 | 0.690 |
Why?
|
| Rats, Inbred F344 | 8 | 2018 | 256 | 0.660 |
Why?
|
| KATP Channels | 1 | 2020 | 10 | 0.660 |
Why?
|
| Glyburide | 1 | 2020 | 9 | 0.660 |
Why?
|
| Muscle, Skeletal | 2 | 2020 | 308 | 0.590 |
Why?
|
| Heat-Shock Response | 1 | 2018 | 22 | 0.580 |
Why?
|
| Animals | 24 | 2020 | 16695 | 0.570 |
Why?
|
| Neurotransmitter Agents | 1 | 2018 | 69 | 0.570 |
Why?
|
| Cytokines | 3 | 2006 | 661 | 0.530 |
Why?
|
| Sympathomimetics | 1 | 2016 | 9 | 0.510 |
Why?
|
| Hypothermia | 2 | 2006 | 13 | 0.510 |
Why?
|
| Ghrelin | 1 | 2016 | 17 | 0.510 |
Why?
|
| Body Temperature Regulation | 2 | 2006 | 8 | 0.460 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 2 | 2006 | 25 | 0.460 |
Why?
|
| Vasoconstrictor Agents | 2 | 2005 | 42 | 0.450 |
Why?
|
| Hyperthermia, Induced | 3 | 2020 | 27 | 0.450 |
Why?
|
| Angiotensin II | 2 | 2005 | 103 | 0.430 |
Why?
|
| Kidney | 6 | 2013 | 363 | 0.420 |
Why?
|
| Action Potentials | 2 | 2013 | 246 | 0.420 |
Why?
|
| Heat Stress Disorders | 2 | 2003 | 8 | 0.420 |
Why?
|
| Prosencephalon | 2 | 2003 | 34 | 0.390 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2013 | 57 | 0.390 |
Why?
|
| Interleukin-1 | 2 | 2003 | 39 | 0.390 |
Why?
|
| Regional Blood Flow | 5 | 2020 | 52 | 0.380 |
Why?
|
| Gene Expression Regulation | 3 | 2006 | 1066 | 0.370 |
Why?
|
| Injections, Intraventricular | 5 | 2016 | 59 | 0.360 |
Why?
|
| Central Nervous System | 2 | 2010 | 150 | 0.340 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2008 | 5 | 0.330 |
Why?
|
| Interleukin-6 | 2 | 2008 | 165 | 0.330 |
Why?
|
| Pressoreceptors | 3 | 2020 | 3 | 0.320 |
Why?
|
| Homeostasis | 2 | 2010 | 193 | 0.310 |
Why?
|
| Male | 14 | 2025 | 22779 | 0.290 |
Why?
|
| Periodicity | 1 | 2007 | 34 | 0.260 |
Why?
|
| Neurons | 2 | 2017 | 1246 | 0.260 |
Why?
|
| Adrenergic Fibers | 1 | 2006 | 3 | 0.260 |
Why?
|
| Microinjections | 3 | 2013 | 50 | 0.230 |
Why?
|
| Research Design | 1 | 2007 | 370 | 0.220 |
Why?
|
| Cyclic N-Oxides | 1 | 2004 | 19 | 0.220 |
Why?
|
| Hemodynamics | 1 | 2003 | 101 | 0.200 |
Why?
|
| Heart Failure | 1 | 2006 | 298 | 0.200 |
Why?
|
| Brain | 2 | 2008 | 1452 | 0.190 |
Why?
|
| Antibodies | 1 | 2003 | 140 | 0.190 |
Why?
|
| Hot Temperature | 2 | 2018 | 141 | 0.190 |
Why?
|
| Medically Underserved Area | 1 | 2023 | 118 | 0.190 |
Why?
|
| Body Temperature | 2 | 2013 | 35 | 0.180 |
Why?
|
| Trust | 1 | 2023 | 157 | 0.180 |
Why?
|
| Antioxidants | 1 | 2004 | 439 | 0.170 |
Why?
|
| Renal Artery | 1 | 2020 | 7 | 0.170 |
Why?
|
| Sympathectomy | 3 | 2005 | 11 | 0.160 |
Why?
|
| Vasoconstriction | 1 | 2020 | 41 | 0.160 |
Why?
|
| Inflammation | 1 | 2025 | 729 | 0.160 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 53 | 0.160 |
Why?
|
| Bicuculline | 2 | 2013 | 18 | 0.150 |
Why?
|
| Ferric Compounds | 1 | 2020 | 62 | 0.150 |
Why?
|
| Contrast Media | 1 | 2020 | 101 | 0.150 |
Why?
|
| Gene Expression | 2 | 2017 | 692 | 0.150 |
Why?
|
| Carbon | 1 | 2020 | 127 | 0.150 |
Why?
|
| Microarray Analysis | 1 | 2017 | 64 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2025 | 744 | 0.130 |
Why?
|
| Receptors, AMPA | 1 | 2017 | 57 | 0.130 |
Why?
|
| Anesthesia | 1 | 2016 | 16 | 0.130 |
Why?
|
| Electrophysiology | 2 | 2010 | 138 | 0.130 |
Why?
|
| Enzyme Inhibitors | 2 | 2013 | 457 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 577 | 0.130 |
Why?
|
| Immunologic Factors | 1 | 2016 | 50 | 0.120 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2017 | 133 | 0.120 |
Why?
|
| Lumbar Vertebrae | 1 | 2016 | 44 | 0.120 |
Why?
|
| Semiconductors | 1 | 2014 | 10 | 0.110 |
Why?
|
| Nanoparticles | 1 | 2020 | 449 | 0.110 |
Why?
|
| Porphyrins | 1 | 2014 | 57 | 0.110 |
Why?
|
| Spinal Nerves | 1 | 2013 | 5 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 649 | 0.100 |
Why?
|
| Thiourea | 1 | 2013 | 8 | 0.100 |
Why?
|
| Lumbosacral Region | 1 | 2013 | 14 | 0.100 |
Why?
|
| Citrulline | 1 | 2013 | 14 | 0.100 |
Why?
|
| Polymers | 1 | 2014 | 151 | 0.100 |
Why?
|
| Mesencephalon | 2 | 2003 | 42 | 0.100 |
Why?
|
| Denervation | 2 | 2002 | 27 | 0.100 |
Why?
|
| RNA, Messenger | 1 | 2017 | 1265 | 0.090 |
Why?
|
| Neural Pathways | 2 | 2003 | 139 | 0.090 |
Why?
|
| Autonomic Denervation | 1 | 2009 | 1 | 0.080 |
Why?
|
| Humans | 4 | 2025 | 42163 | 0.070 |
Why?
|
| Kinetics | 1 | 2010 | 698 | 0.070 |
Why?
|
| Third Ventricle | 1 | 2008 | 4 | 0.070 |
Why?
|
| Glutamic Acid | 1 | 2009 | 131 | 0.070 |
Why?
|
| Electrodes | 1 | 2008 | 57 | 0.070 |
Why?
|
| Fourier Analysis | 1 | 2007 | 45 | 0.070 |
Why?
|
| Age Factors | 1 | 2010 | 1139 | 0.070 |
Why?
|
| Spectrum Analysis | 1 | 2007 | 59 | 0.060 |
Why?
|
| Adrenal Glands | 1 | 2006 | 17 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 928 | 0.060 |
Why?
|
| Cerebrospinal Fluid | 1 | 2005 | 20 | 0.060 |
Why?
|
| Hair | 1 | 2025 | 38 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1112 | 0.060 |
Why?
|
| Computer Systems | 1 | 2004 | 19 | 0.060 |
Why?
|
| Spin Labels | 1 | 2004 | 12 | 0.060 |
Why?
|
| Losartan | 1 | 2004 | 35 | 0.050 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2004 | 37 | 0.050 |
Why?
|
| Superoxides | 1 | 2004 | 57 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 310 | 0.050 |
Why?
|
| Splanchnic Circulation | 1 | 2003 | 4 | 0.050 |
Why?
|
| Tail | 1 | 2003 | 5 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2003 | 29 | 0.050 |
Why?
|
| Mexico | 1 | 2025 | 286 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2004 | 151 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 708 | 0.050 |
Why?
|
| Hindlimb | 1 | 2003 | 32 | 0.050 |
Why?
|
| Splanchnic Nerves | 1 | 2003 | 2 | 0.050 |
Why?
|
| Microspheres | 1 | 2003 | 49 | 0.050 |
Why?
|
| Stomach | 1 | 2003 | 50 | 0.050 |
Why?
|
| Synaptic Transmission | 1 | 2004 | 156 | 0.050 |
Why?
|
| Chloralose | 1 | 2003 | 1 | 0.050 |
Why?
|
| omega-N-Methylarginine | 1 | 2003 | 8 | 0.050 |
Why?
|
| Anesthetics, Intravenous | 1 | 2003 | 4 | 0.050 |
Why?
|
| Kynurenic Acid | 1 | 2003 | 9 | 0.050 |
Why?
|
| GABA Antagonists | 1 | 2003 | 29 | 0.050 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2003 | 45 | 0.050 |
Why?
|
| Rest | 1 | 2003 | 33 | 0.050 |
Why?
|
| N-Methylaspartate | 1 | 2003 | 58 | 0.050 |
Why?
|
| Sinus of Valsalva | 1 | 2002 | 3 | 0.050 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2003 | 93 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2002 | 65 | 0.050 |
Why?
|
| Cervical Vertebrae | 1 | 2002 | 18 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2025 | 733 | 0.050 |
Why?
|
| Heart | 1 | 2003 | 181 | 0.050 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2002 | 67 | 0.050 |
Why?
|
| Spinal Cord Injuries | 1 | 2002 | 68 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2003 | 170 | 0.040 |
Why?
|
| Universities | 1 | 2025 | 539 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2025 | 916 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 683 | 0.040 |
Why?
|
| Magnetics | 1 | 2020 | 43 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 101 | 0.040 |
Why?
|
| Particle Size | 1 | 2020 | 267 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2020 | 403 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 686 | 0.040 |
Why?
|
| Risk Factors | 1 | 2025 | 3942 | 0.030 |
Why?
|
| Electric Conductivity | 1 | 2014 | 55 | 0.030 |
Why?
|
| Materials Testing | 1 | 2014 | 99 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 1554 | 0.030 |
Why?
|
| United States | 1 | 2025 | 5072 | 0.030 |
Why?
|
| Female | 2 | 2025 | 24018 | 0.020 |
Why?
|
| Aged | 1 | 2025 | 7982 | 0.020 |
Why?
|
| Middle Aged | 1 | 2025 | 11819 | 0.020 |
Why?
|
| Neoplasms | 1 | 2020 | 1341 | 0.020 |
Why?
|
| Adult | 1 | 2025 | 13458 | 0.020 |
Why?
|
| Mice | 1 | 2020 | 6490 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 1679 | 0.020 |
Why?
|